

NC Department of Health and Human Services

Immunization Branch Update

North Carolina Immunization Coalition, July 2022

Carrie Blanchard, PharmD, MPH
Immunization Branch Interim Director

Beth Meadows, RN, MSN
Field Services Unit Manager



NC DEPARTMENT OF
**HEALTH AND
HUMAN SERVICES**





ABOUT THE NORTH CAROLINA IMMUNIZATION BRANCH

What is the IB?

The North Carolina Immunization Branch, part of the N.C. Division of Public Health, oversees the North Carolina Immunization Program **(NCIP)**.


The NCIP provides recommended vaccines for eligible children from birth through 18 years of age.

Through the NCIP, vaccines are distributed to health care providers at no charge.

Our Mission

To keep children in their medical homes

To remove cost as a barrier to age-appropriate immunizations




The percentage of pediatricians who administer vaccines to children in North Carolina who participate in this program.

During COVID-19, the IB deployed a special COVID-19 Program to address the unique and dynamic needs of North Carolinians. The NC COVID-19 program has been recognized nationally for their data-driven approach to equity and decision-making. Now, the IB is integrating their COVID-19 work with standing IB functions for a new, robust Branch to serve NC.

CONSTANT AVAILABILITY IS THE WAY FORWARD



A SHOT IN EVERY ARM ISN'T POSSIBLE WITHOUT



Moving from mass vaccination → routine, practice-based vaccination

Ensuring all populations have vaccine access and never missing an opportunity to have vaccine conversations or administer vaccine

77%

% of parents say they trust their child's **pediatrician** to provide **reliable information** on vaccines for children*

44%


% of unvaccinated persons report that would feel **most comfortable** getting vaccinated at their **doctor's office****

46%

% of parents with an unvaccinated child aged 5-11 who say hearing from people they trust would make them much more likely to get their child vaccinated

100%

Of locations with vaccine on hand = 0% missed opportunities to counsel, validate, and vaccinate



COVID-19 VACCINE: CURRENT TRENDS

Key Trends as of 7/11/22




As COVID-19 vaccine demand slows, it is more important than ever for provider locations to keep COVID vaccine on-hand alongside all standard immunizations so that they never miss an opportunity to vaccinate

- **18% of North Carolina population is Up to Date on their Vaccine Journey**
 - No change week-over-week
- **318,260 people have received their Second Booster dose**
 - That makes up 15.6% of the current eligible Second Booster population.
 - Second Booster Dose % increased 0.4% week-over-week
- **51.8% of the Booster Eligible Population are Boosted**
 - Opportunities to administer booster doses may be intermittent and unpredictable. Providers should "expect the unexpected" by keeping "A Vial in Every Fridge"
 - Minimal change week-over-week
- **7.2% of Pfizer or Moderna dose 1 recipients are overdue (63 days) for their dose 2**
- **13,422 doses have been administered to individuals under 5**
 - That makes up 2% of the current eligible population
- **Weekly Dose 1 Vaccine rates remain at the low of 1 of every 1,000 unvaccinated eligible residents**
 - Dose 1 demand has steadily decreased since the beginning of 2022
 - 66% of the total population has received their first dose

Up to Date - Breakdown



The purpose of this slide is to track North Carolina residents who are Up-to-Date on their Vaccination Journey. Calculation logic can be found in the appendix. Data as of 7/11/2022.



Up-to-Date
17.7%

Total: **1,859,985**
 Second Booster: **318,260**
 Booster: **1,412,763**
 Primary Series: **128,962**

Top 10 Counties

ORANGE COUNTY	36.4%
DURHAM COUNTY	31.4%
WAKE COUNTY	28.6%
BUNCOMBE COUNTY	25.2%
HYDE COUNTY	23.0%
MECKLENBURG COUNTY	21.2%
WATAUGA COUNTY	20.3%
NEW HANOVER COUNTY	18.1%
FORSYTH COUNTY	18.0%
GUILFORD COUNTY	17.5%

Bottom 10 Counties

GRAHAM COUNTY	7.3%
ONSWLOW COUNTY	7.5%
CURRITUCK COUNTY	7.7%
DUPLIN COUNTY	7.8%
ROBESON COUNTY	7.8%
MONTGOMERY COUNTY	8.0%
POLK COUNTY	8.0%
PERQUIMANS COUNTY	8.0%
HOKE COUNTY	8.1%
ROWAN COUNTY	8.1%


Key Takeaways:

- Most of the State is not Up to Date on their COVID vaccinations – an important reason for Providers to be prepared for with a Vial in Every Fridge
- Minimal increase week-over-week



Booster Eligible, No Booster - Breakdown

The visual below displays the percentage of individuals who have yet received a booster dose but are booster eligible according to CDC guidelines. Calculation logic can be found in the appendix. Data as of 7/11/2022.




Booster Eligible, No Booster

48.2%
(3,214,189)

Key Takeaways:

- Because nearly 64.5% of Latinx recipients are overdue for their booster dose, maintaining a supply of COVID-19 vaccine capable of boosting these individuals is part of providers' commitment to health equity.
- Minimal change month-to-month



Top 10 Counties	
ROBESON COUNTY	58.1%
DUPLIN COUNTY	57.9%
ONSWLOW COUNTY	57.1%
CURRITUCK COUNTY	57.0%
HOKE COUNTY	56.9%
POLK COUNTY	56.2%
WILKES COUNTY	55.6%
SAMPSON COUNTY	54.9%
CAMDEN COUNTY	54.9%
MARTIN COUNTY	54.8%

Bottom 10 Counties	
ORANGE COUNTY	35.0%
DURHAM COUNTY	40.4%
BRUNSWICK COUNTY	40.5%
PAMLICO COUNTY	40.7%
CHATHAM COUNTY	41.3%
BUNCOMBE COUNTY	41.5%
TRANSYLVANIA COUNTY	41.6%
HYDE COUNTY	41.8%
HENDERSON COUNTY	42.7%
WAKE COUNTY	42.8%

	5-11	12-17	18-24	25-29	30-39	40-49	50-64	65-74	75+	Grand Total
Female	87.3%	69.1%	60.8%	60.9%	56.2%	50.6%	41.1%	29.5%	29.8%	46.6%
Male	87.6%	70.6%	66.1%	66.0%	59.8%	54.2%	44.6%	30.4%	27.8%	50.0%
Grand Total	87.4%	69.8%	63.0%	63.1%	57.9%	52.3%	42.8%	30.0%	29.1%	48.2%

Percent Booster Eligible, No Booster: 27.8% to 87.6%

Statewide Vaccination Trends: Booster % Intersectional Breakdown




The visual below displays the percentage of individuals who have received a booster dose out of the booster eligible population according to CDC guidelines. Calculation logic can be found in the appendix. Data as of 7/11/2022.

Race by Age Group

		5-11	12-17	18-24	25-29	30-39	40-49	50-64	65-74	75+	Grand Tot..
American Indian or Alaskan Native	Female	9.8%	22.8%	32.2%	31.8%	35.0%	40.7%	50.0%	61.7%	64.3%	44.5%
	Male	10.1%	24.6%	28.3%	26.5%	35.2%	39.9%	46.9%	61.7%	64.8%	42.7%
Asian or Pacific Islander	Female	13.9%	44.8%	56.3%	51.6%	57.3%	62.6%	66.4%	71.5%	70.8%	57.7%
	Male	13.5%	42.3%	51.0%	47.2%	55.0%	61.3%	66.0%	70.5%	73.8%	55.1%
Black or African-American	Female	8.1%	24.5%	32.5%	29.7%	34.8%	47.0%	61.1%	74.0%	73.7%	51.5%
	Male	7.7%	23.3%	28.9%	27.5%	32.6%	42.2%	56.3%	71.5%	74.3%	47.0%
White	Female	14.8%	35.9%	42.3%	42.7%	47.8%	52.0%	59.7%	70.8%	71.1%	56.6%
	Male	14.5%	34.1%	36.5%	36.6%	43.6%	48.7%	56.6%	70.2%	72.9%	53.6%
Grand Total		12.6%	30.2%	37.0%	36.9%	42.1%	47.7%	57.2%	70.0%	70.9%	51.8%

Ethnicity by Age Group

		5-11	12-17	18-24	25-29	30-39	40-49	50-64	65-74	75+	Grand Tot..
Hispanic	Female	7.3%	22.6%	32.0%	31.8%	34.4%	39.9%	51.2%	59.9%	60.4%	38.0%
	Male	7.6%	21.3%	25.5%	26.3%	28.7%	34.3%	46.5%	60.8%	62.8%	33.3%
Non-Hispanic	Female	14.0%	35.3%	42.3%	41.6%	46.8%	52.5%	61.3%	72.0%	72.0%	56.7%
	Male	13.6%	33.5%	37.3%	36.9%	43.9%	49.8%	58.2%	71.0%	73.3%	53.8%
Grand Total		12.6%	30.2%	37.0%	36.9%	42.1%	47.7%	57.2%	70.0%	70.9%	51.8%




Note: Data does *not* include federal entity administrations.

STATEWIDE VACCINE RATES BY AGE


Percent of Population Vaccinated with at Least One Dose by Age – North Carolina



Weekly Trend



Cumulative Total





COVID-19 NEWS: UPDATES

COVID-19 AND ROUTINE VACCINATION

*Make sure your team is prepared to **Move Forward Together***



Use every clinic visit as an opportunity to vaccinate!



COVID-19 vaccine wastage may occur.



Consider vaccinating children who are not current patients.



Promote v-safe, the after-vaccination health checker!



Remember: all clinic visits serve as opportunities for children to get COVID-19 vaccines alongside other routine vaccines that may have been missed due to COVID-related disruptions.


HIGH LEVEL HIGHLIGHTS

Thanks to healthcare professionals like you, there have been over 13,422 administrations to children 5 and under across NC!

5 & Under Vaccine Rollout Recap

- COVID-19 vaccines are now available to anyone over 6 months of age and patients have a choice.
- A COVID-19 vaccine primary series is recommended for everyone 6 months and older, and those 5+ should get at least 1 booster dose, if eligible.
- COVID-19 vaccines may be administered without regard to timing of other vaccines. This includes simultaneous administration of COVID-19 vaccine and other vaccines on the same day.

Vaccines and Boosters Statewide




What's New?

- Comirnaty has been approved for a 2 dose primary series in those aged 12 and older. Statewide Orders will be updated soon.
- [The NC DHHS Dashboard](#) has been updated to include data for children 5 and under
- [Moderna 6-11 COVID-19 Vaccine Codes](#) have been updated.

5 AND UNDER VACCINE TRACKER

- The CDC recommends that all children 6 months through 5 years of age should receive a COVID-19 vaccine.
- If you receive vaccines for children 5 and under in the coming days, **administration can begin!**



**Ctrl + Click Here
for the DHHS
Press Release**



**Ctrl + Click for
Statewide Standing
Orders**






Kids At Least One Dose % Comparison

NCDHHS At Least One Dose % Ages 0-4, 5-11, 12-15 Comparison COVID-19 Response

Description: The visual below displays compares the At Least One Dose % of kids ages 0-4, 5-11, 12-15 from their respective CDC authorization dates.



Doses Administered to Children 5 and Under: 13, 422

Unique Providers: 456

Unique Administration Counties: 80

Age 12-15 approval on 5/11/2021
Age 5-11 approval on 11/01/2021
Age 0-4 approval on 6/18/2022

Note: Data does not include federal entity administrations

5 AND UNDER BENEFITS & SAFETY

Children who get COVID-19 can get very sick, require treatment in a hospital, and have died in rare cases.




Vaccinating eligible children helps prevent them from getting very sick, and helps prevent serious short- and long-term complications of COVID-19.



Before recommending COVID-19 vaccination for children, scientists conducted clinical trials with thousands of children to make sure vaccination was safe and effective.



Tens of millions of children and teens ages 5 through 17 years have received a first dose of the COVID-19 vaccine. Ongoing safety monitoring shows that COVID-19 vaccination continues to be safe for children and teens.



The safety data for the Pfizer vaccine is based on 1,678 children under age 5 who received a third dose when omicron was the main variant in circulation. **A preliminary analysis shows the 3-dose series is 80% effective against the omicron variant.**



Last winter, **children younger than age 5 were hospitalized with COVID-19 at five times the rate of the pandemic peak**, according to the CDC.

Pfizer and Moderna for Kids Under 6

	Moderna: 6 Mths to <6 Yrs Doses: 2	Pfizer: 6 Mths to <5 Yrs Doses: 3
How much is in each dose?	25 micrograms <i>(1/4 of adult dose of 100 mcg)</i>	3 micrograms <i>(1/10 of adult dose of 30 mcg)</i>
What is the current timeline? <i>Timeline may differ for those with compromised immune systems.</i>	The second dose is given 4 to 8+ weeks after the first dose.	The second dose is given 3 to 8+ weeks after the first dose. The third dose is given 8+ weeks after the second
When does protection start?	6 weeks after 1st dose	13 weeks after 1st dose
How many kids took part in the clinical trials?	6,000 children	1,500 children
Are there side effects?	Fever, temporary sore arm, feeling achy for a day or two, headaches	Fatigue, temporary sore arm, feeling achy for a day or two, headaches, mild fever

Vaccines for Immune Compromised Kids

Which vaccine did you get?	Vaccination schedule for moderately or severely immunocompromised people ONLY.			
Pfizer 6 months - 4 years Healthy & Immune Compromised	1st dose	At least 3 Weeks	2nd dose	8+ Weeks 3rd dose
Pfizer 5 years - 11 years Immune Compromised	1st dose	3-8+ Weeks	2nd dose	4+ Weeks 3rd dose 3+ Months Booster
Moderna 6 months - 5 years Immune Compromised	1st dose	4+ Weeks	2nd dose	4+ Weeks 3rd dose
Moderna 6 years - 11 years Immune Compromised	1st dose	4+ Weeks	2nd dose	4+ Weeks 3rd dose


MODERNA 6 TO 17 CDC RECOMMENDATION

The CDC has now **recommended** the Moderna COVID-19 vaccine for children between the ages of 6 to 17 following FDA **authorization**.

- [Updated Statewide Standing Orders](#)
- [6-11 Moderna Fact Sheet for Healthcare Providers](#)
- [12-17 Moderna Fact Sheet for Healthcare Providers](#)

MODERNA 6 TO 17 VACCINE TRACKER

The CDC recommends that all children 6 years to 17 years should receive a COVID-19 vaccine.




Eligibility Guidance

6 to 11 Guidance Details

Children between the ages of **6 and 11 years** are now eligible for:

- A Moderna **two-dose** primary series OR
- A Moderna **three-dose** primary series for **immunocompromised individuals**












12 Years and Older Guidance Details

Children between the ages of **12 and 17** are now eligible for:

- A **two-dose** primary series OR
- A **three-dose** third primary series for **immunocompromised individuals**

AUTHORIZED MODERNA COVID-19 VACCINE PRODUCTS

- Note the Moderna 6 to 11 product is labeled “**BOOSTER DOSES ONLY**” but is also authorized for primary series in 6–11 year olds. Booster and primary doses are 0.5mL.
- The 6 to 11 blue cap with teal border is not yet manufactured in US.
- 12 and up formulation does not indicate age on the label, but is the same product used for 18+.
- Please see [the Dear HCP Letter](#) for more information.
- The [State Standing Order](#) has been updated. 6 month through 17-year-olds who get a Moderna primary series are not currently recommended to receive boosters.

	Primary Series (≥12 years of age) Booster Doses (≥18 years of age)	Primary Series (6-11 years of age) Booster Doses (≥18 years of age)	Primary Series (6 months-5 years of age)
Dose Per Vial	Primary Series Doses only: maximum of 11 doses (range: 10-11 doses) Booster Doses only: maximum of 20 doses Combination of Primary Series Doses and Booster Doses: maximum of 20 doses	Primary Series Doses: 5 doses Booster Series Doses: 5 doses	Primary Series Doses only: 10 doses
Dose Volume	Primary Series Dose: Each 0.5 mL Booster Dose: 0.25 mL	Primary Series Dose: 0.5 mL Booster Series Dose: 0.5 mL	Primary Series Dose: Each 0.25 mL
Vial Cap Color	Red 	Dark Blue 	Dark Blue 
Vial Label	Blue border  NDC 80777-273-10	Purple border  NDC 80777-275-05	Magenta border  NDC 80777-279-05
Carton	Blue border  NDC 80777-273-99	Purple border  NDC 80777-275-99	Magenta border  NDC 80777-279-99

The Moderna COVID-19 Vaccine vial labeled “BOOSTER DOSES ONLY” is also authorized to provide Primary Series Doses (0.5 mL each) for individuals 6 through 11 years of age. Please see the Dear HCP Letter for more information.

Aging Up Resources

- CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on **their age on the day of vaccination regardless of size or weight.**
- All doses of the primary series should be from the same manufacturer, when possible. The products are **NOT** meant to be interchangeable for this age group, although in certain circumstances may be adjusted according to current age.
- [Moderna "Aging Up"](#)
- [Pfizer-BioNTech "Aging Up"](#)

Moderna COVID-19 Vaccine
for Children who Transition from a Younger to Older Age Group

CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on the day of vaccination.

- If a person moves from a younger age group to an older age group during the primary series, they should receive the vaccine product and dosage for the older age group for all subsequent doses.
- FDA emergency use authorization (EUA) allows for different dosing for certain age transitions, which are not considered vaccine administration errors and do not need to be reported to the Vaccine Adverse Event Reporting System (VAERS).

Children who turn from age 5 to age 6 years

Recommended: Children who started a primary series and turned from age 5 to age 6 years before completion of the series should receive:

Dose 1 (Age 5): 0.25 mL (25 mcg) of the product authorized for children ages 6 months–5 years (dark blue cap/magenta label border) → 4-8 weeks → Child turns 6 → Dose 2 (Age 6): 0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border)

Acceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete. Either dose may be:

- 0.25 mL (25 mcg) of the product authorized for children ages 6 months–5 years (dark blue cap/magenta label border), or
- 0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border)

Pfizer-BioNTech COVID-19 Vaccine
for Children who Transition from a Younger to Older Age Group

CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on the day of vaccination.

...es from a younger age group to an older age group during the primary series or between the primary series and booster dose(s), they should receive the vaccine product and dosage for the older age group for all subsequent doses. ...y use authorization (EUA) allows for different dosing for certain age transitions, which are not considered vaccine errors and do not need to be reported to the Vaccine Adverse Event Reporting System (VAERS).

Children who turn from age 4 to age 5 years

Recommended: Children who started a primary series and turned from age 4 to age 5 years between dose 1 and dose 2 primary series should receive:

Dose 1 (Age 4): 0.20 mL (10 mcg) of the product authorized for children ages 6 months–4 years (maroon cap and label border) → 3-8 weeks → Child turns 5 → Dose 2 (Age 5): 0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border) → 8 weeks → Dose 3 (Age 5): 0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)

Recommended: Children who started a primary series and turned from age 4 to age 5 years between dose 2 and dose 3 primary series should receive:

Dose 1 (Age 4): 0.20 mL (10 mcg) of the product authorized for children ages 6 months–4 years (maroon cap and label border) → 3-8 weeks → Dose 2 (Age 4): 0.20 mL (10 mcg) of the product authorized for children ages 6 months–4 years (maroon cap and label border) → 8 weeks → Child turns 5 → Dose 3 (Age 5): 0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)

Acceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete. Primary series using the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5–11 years (orange cap and label border):

Dose 1: Age 4 or 5 → 3-8 weeks → Dose 2: Age 4 or 5

AVAILABLE FACT SHEETS


Please see the following resources for the children 5 and under, and Moderna vaccines for children 6-17 years vaccine products:

- [Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group](#)
- [Pfizer-BioNTech COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group](#)
- [Summary Document and Chart for Interim Clinical Considerations](#)
- [At-A-Glance COVID-19 Vaccination Schedules](#)



Summary Document for Interim Clinical Considerations

for Use of COVID-19 Vaccines Currently Authorized or Approved in the United States



COVID-19 vaccine products currently approved or authorized in the United States

Pfizer-BioNTech							
Age indication	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses	
				Dose	Injection volume	Dose	Injection volume
6 months–4 years	Maroon	Maroon	Yes	3 µg	0.2 mL	NA	NA
5–11 years	Orange	Orange	Yes	10 µg	0.2 mL	10 µg	0.2 mL
12 years and older	Purple	Purple	Yes	30 µg	0.3 mL	30 µg	0.3 mL
12 years and older	Gray	Gray	No	30 µg	0.3 mL	30 µg	0.3 mL

Moderna							
Age indication	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses	
				Dose	Injection volume	Dose	Injection volume
6 months–5 years	Dark blue	Magenta	No	25 µg	0.25 mL	NA	NA
6–11 years	Dark blue	Purple	No	50 µg	0.5 mL	NA	NA
12–17 years	Red	Light blue	No	100 µg	0.5 mL	NA	NA
18 years and older	Red	Light blue	No	100 µg	0.5 mL	50 µg	0.25 mL
18 years and older	Dark blue	Purple	No	NA	NA	50 µg	0.5 mL

Janssen							
Age indication	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses	
				Dose	Injection volume	Dose	Injection volume
18 years and older	Blue	Purple	No	5×10 ¹⁰ viral particles	0.5 mL	5×10 ¹⁰ viral particles	0.5 mL

FDA RECOMMENDS OMICRON BOOSTER COMPONENT



- The FDA recommended inclusion of an Omicron BA.4/5 component for COVID-19 vaccine booster doses in formulation.
- Vaccine manufacturers have already reported data from adult clinical trials with bivalent and monovalent formulations. The FDA has advised manufacturers to develop modified vaccines to include an omicron BA.4/5 component to the existing strain for a bivalent Fall booster.

“As we move into the fall and winter, it is critical that we have safe and effective vaccine boosters that can provide protection against circulating and emerging variants to prevent the most severe consequences of COVID-19.”



Read the full article [here!](#)





COVID-19 VACCINE: COMMUNICATION RESOURCES

5 AND UNDER COMMUNICATION MATERIALS

PROTECT THEM FROM COVID-19

Children 6 months and older can now get a safe, effective and free COVID-19 vaccine.

Did you know children, including infants, can get COVID-19? Cases in children can result in hospitalization, death, MIS-C (inflammation in different parts of the body) and long-term side effects.

The Centers for Disease Control and Prevention (CDC) recommends all children who are eligible get the COVID-19 vaccine. Parents should get their children vaccinated to give them their best shot at protection.

The COVID-19 vaccine has been tested in clinical trials with children ages 6 months to 11 years and no safety concerns or serious side effects were noted in the clinical trials.

COVID-19 vaccines are free, even if you don't have insurance and regardless of your immigration status.

For more information about the COVID-19 vaccine, visit [MySpotNC.gov](#) to find a vaccine location near you.

NC Department of Health and Human Services • [MySpotNC.gov](#)
NCDHHS is an equal opportunity employer and provider. • 06/2022



Where should you go to get your child vaccinated?



Kids ages 3 to 11 years old

Any location that has the kids ages 3 to 11 vaccines available, including at their pediatrician or doctor's office, local pharmacies and grocery stores.



Babies and toddlers ages 6 months to 2 years old

PROTEGE A *los niños*
VACÚNALOS
CONTRA EL COVID-19

Los niños pueden contraer el COVID-19, al igual que todos los demás.

Los niños contagiados con COVID-19 corren el riesgo de experimentar efectos a largo plazo a causa del virus, incluyendo dolores de cabeza, pérdida de memoria y fatiga muscular. La vacuna de Pfizer contra el COVID-19 ya está disponible y es recomendada para niños de 5 a 11 años. La vacuna para niños es una dosis más baja y es gratuita, segura y efectiva.

La vacuna fue probada en ensayos clínicos y se recomienda vacunar a los niños para protegerlos contra la enfermedad grave. **No esperes para vacunar a tus hijos.**

Dales la mejor oportunidad para que puedan...

Ir a la escuela

Estar con sus familias

Under 5 Vaccine promotional material is available in English and Spanish! Access flyers and fact sheets [here](#).

kids HAVE A
SPOT
TO TAKE THEIR
SHOT.

COVID-19 Vaccines for Kids

Side effects and What to Expect

Vaccines have significantly reduced many childhood diseases, such as diphtheria, measles, and chickenpox.

Some diseases, such as polio, have been eliminated in the United States due to vaccination.

Most side effects of vaccines are usually minor and short-lived.

Serious vaccine reactions are extremely rare and no serious side effects were reported during the COVID-19 clinical trials.

Side effects for the COVID-19 vaccine for children 5-11 were generally mild and similar to side effects seen in the 16-25 age group.

Your child may experience a temporarily sore arm, headache and being tired or so.

Myocarditis, an inflammation of the heart muscle, is an extremely rare side effect from the vaccine and more common in people with COVID-19 infection.

Mostly mild cases were reported in adolescents and young adults after vaccination. Most people usually recover on their own or need minimal treatment. No cases of myocarditis were reported during the clinical trials of children 5-11.

PROACTIVE CAMPAIGNS

PROTÉGETE A TI Y A LOS DEMÁS.
¡VACÚNATE!

Recuperemos el verano en Carolina del Norte.

Ofrécete como voluntario para ayudar a otros en nuestra comunidad a vacunarse contra el COVID-19.

Fecha del evento
Ubicación del evento de voluntariado
Dirección del sitio
Continuación de la dirección del sitio

Contacta a [nombre, teléfono, correo electrónico] para saber cómo puedes participar.

YOU HAVE A SPOT. TAKE YOUR SHOT.

BRING SUMMER BACK TO NORTH CAROLINA.

Get a safe, effective and free COVID-19 vaccine and help others do the same.

Learn more at covid19.ncdhhs.gov/BringSummerBack or schedule your appointment at MySpot.nc.gov.

Remember to practice your 3 Ws: Wear, Wait, Wash.

NC Department of Health and Human Services • YourSpotYourShot.nc.gov
NCDHHS is an equal opportunity employer and provider. • 04/2021

Bring Summer Back (2021)

It is estimated that the campaign reached more than 1.5 million North Carolinians and involved more than 350 registered partners and 7,000 volunteers across the state.

SPRING INTO SUMMER

COVID-19 vaccines and boosters make for safer vacations, camps, reunions and more.

Make sure everyone who is eligible for a vaccine in your family is up to date for a healthier summer.

Make an appointment today at MySpot.nc.gov, or visit SpringIntoSummer.nc.gov to learn how you can help others get vaccinated.

NC Department of Health and Human Services • MySpot.nc.gov
NCDHHS is an equal opportunity employer and provider. • 03/2022
30,000 copies of this public document were printed at a cost of \$0.19 each.

YOU HAVE A SPOT. TAKE YOUR SHOT.

UN VERANO SALUDABLE

Las vacunas y las dosis de refuerzo contra el COVID-19 permiten que disfrutes de manera más segura las vacaciones, los campamentos, las reuniones y más.

Asegúrate que todas las personas de tu familia que sean elegibles estén al día con su vacunación para que disfruten de un verano saludable.

Haz una cita hoy en Vacunate.nc.gov o visita UnVeranoSaludable.nc.gov para aprender cómo puedes ayudar a los demás a vacunarse.

Departamento de Salud y Servicios Humanos de Carolina del Norte
Vacunate.nc.gov • NCDHHS es un empleador y proveedor de igualdad de oportunidades

PROTÉGETE A TI Y A LOS DEMÁS.
¡VACÚNATE!

DEPARTAMENTO DE SALUD Y SERVICIOS HUMANOS DE CAROLINA DEL NORTE

Spring Into Summer (2022)

Currently the campaign has 280 registered partners and is in its second statewide distribution of printed materials.

FLYERS:

YOU HAVE A SPOT. TAKE YOUR SHOT.

PROTECT YOURSELF, FAMILY AND COMMUNITY.
Get a safe, effective and free COVID-19 vaccine.

Learn more at YourSpotYourShot.nc.gov
COVID-19 Vaccination Help Center,
toll-free at 888-675-4567.

NC Department of Health and Human Services • YourSpotYourShot.nc.gov
NCDHHS is an equal opportunity employer and provider. • 02/2021

Todos de 5 años o más son elegibles para una dosis de refuerzo de la

VACUNA CONTRA EL COVID-19

Las dosis de refuerzo ahora están disponibles para todos los habitantes de Carolina del Norte de 5 años o más para fortalecer y extender las protecciones contra el COVID-19. Si eres elegible, puedes recibir una dosis de refuerzo ahora.

Si recibiste una vacuna de Moderna o Pfizer:
Vacúnate con la dosis de refuerzo 5 meses después de tu segunda dosis. Las personas que recibieron sus vacunas contra el COVID-19 fuera de los EE. UU. con una marca no autorizada podrán recibir una dosis de refuerzo de Pfizer cuando sean elegibles.

Si recibiste una vacuna de Johnson & Johnson:
Vacúnate con la dosis de refuerzo 2 meses después de haber recibido tu vacuna.

Los adultos de 18 años o más pueden recibir cualquier marca de la vacuna para su dosis de refuerzo. Los jóvenes de 5 años o más solo pueden recibir la dosis de refuerzo de Pfizer.

- Se recomienda que los adultos 18 años o más se vacunen con la dosis de refuerzo de Moderna o Pfizer, en lugar de la dosis de refuerzo de Johnson & Johnson, a menos que tengan una razón médica para no recibir una vacuna de ARNm.
- Cualquier persona de 5 años o más con un sistema inmunológico comprometido de nivel moderado a grave debe recibir una dosis adicional de la vacuna contra el COVID-19.
- No necesitas una nota del médico para recibir una dosis de refuerzo. Deberás saber las fechas de tu vacunación y la marca de las vacunas que recibiste contra el COVID-19 anteriormente.
- Las tarjetas de vacunación pueden no ser necesarias para recibir una dosis de refuerzo, pero podrán ser útiles para documentar tus vacunas para algunos requisitos de viaje o entrada a sitios.
- Es posible que haya disponible vacunación en el hogar (a domicilio) y transporte gratuito.

Para más información y para encontrar un centro de vacunación, visita Vacunate.nc.gov o llama al 1-888-675-4567. **PROTEGETE A TI Y A LOS DEMÁS ¡VACÚNATE!**

Departamento de Salud y Servicios Humanos de Carolina del Norte • Vacunate.nc.gov
NCDHHS es un proveedor y empleador que ofrece oportunidad igual a todos. • 05/2022

PRESENTATIONS:

Stay Safe, Stay Informed
The COVID-19 Virus and Vaccines in North Carolina

Don't wait to vaccinate.

If you are already vaccinated, talk with your unvaccinated family and friends. Share your experience, help them get accurate information, and urge them to get their shot now. It could save their lives.

#WhyIGotMyShot
because of my FAMILY

#PorEsOmeVacuné
Por volver a la normalidad y mantener a mi familia y comunidad a salvo.

vacunarse ahora. Podrías salvarles la vida.

NC DEPARTMENT OF HEALTH AND HUMAN SERVICES

DEPARTAMENTO DE SALUD Y SERVICIOS HUMANOS DE CAROLINA DEL NORTE

BANNERS:

Have questions about COVID-19 vaccines?

COVID-19 vaccines: Safe, effective, free.

SOCIAL AND VIDEO:

SPRING INTO SUMMER
TeenVaxFacts.com

NC Teens: Get your COVID-19 vaccine & enjoy spring festivities!
Spring break, prom and graduation are around the corner. Don't miss out on the fun. Get both doses of the Pfizer-BioNTech COVID-19 vaccine and a booster 5 months later.

Gabriela M. Maradiaga Panayotti, MD
Pediatrician, Duke Health



MONKEYPOX UPDATE

Monkeypox- JYNNEOS Key Points

SubQ, 2 dose series, 28 days apart

Live, but non-replicating (no min interval between live virus vaccines)

Vaccine allocated in phases to states via SNS

Post-exposure, within 14 days; ideally within 4 days

LHD Toolkit with Standing Order Template sent to LHDs 7/7

Expiration date on carton, not on vial. Expiration date can be found at [Monkeypox \(hhs.gov\)](https://www.hhs.gov/monkeypox)

Can be stored frozen up to the expiration date or refrigerated up to 8 weeks (this differs from the package insert)

Vaccine must be added as private inventory; NCIR schedule has not been updated yet

MONKEYPOX (MPXV) EPIDEMIOLOGY

Case Count


- 866 known Monkeypox cases in the US, 6 of which are in North Carolina
- **No reported deaths**

Demographics

- Most cases reported in men between the ages of **35-36**
- The majority of patients have had skin rash

2022 U.S. Map & Case Count


Updated July 11, 2022 [Print](#)



[Click Here for the Monkeypox Case Count Map](#)

MEDICAL COUNTERMEASURES: VACCINE OPTIONS

Both options thought to be ~85% effective at preventing monkeypox.

Name	Indication	Dosing & Administration	Availability	Storage and Handling	Notes
 JYNNEOS Also known as: Imvamune Imvanex	FDA approved for prevention of smallpox & monkeypox in adults 18+ Individuals <18 can be treated under expanded access IND.	2 doses (0.5 mL each) administered 4 weeks apart. Subcutaneous injection	SNS request; ~ 72,000 doses in SNS and growing	Keep frozen at -25°C to -15°C (-13°F to +5°F). Once thawed, the vaccine may be kept at +2°C to +8°C (+36°F to +46°F) for 8 weeks	Live attenuated virus vaccine; non-replicating modified vaccinia Ankara-Bavarian Nordic (MVA-BN) Ships frozen from SNS Can transport refrigerated for immediate/short term use Single dose vials; SNS does not provide ancillary supplies
ACAM2000	FDA approved for smallpox prevention in adults and pediatrics >1 y.o. Expanded access IND for monkeypox	1 drop of vaccine suspension via scarification using bifurcated needle. CDC Training Videos for ACAM2000 administration	SNS Request; > 100 Million doses in SNS	Prior to reconstitution, store frozen at -15°C to -25°C (5°F to -13°F); may also be stored refrigerated at 2°C to 8°C (36°F to 46°F) for up to 18 months. Diluent stored at room temperature of 15°C to 30°C (59°F to 86°F).	Live vaccinia virus Myocarditis risk Contraindications for severe immunocompromise and peds <1. Only administered by trained individuals; previous vaccination recommended Counseling on covering wound and handling bandages 100 doses per vial; comes with diluent and 100 bifurcated needles; transfer syringes not included.



Denotes preferred MCM

NORTH CAROLINA'S RESPONSE PLAN

Phase 1 – “PEP++”

- Vaccine pre-positioned in seven local health departments across the state
 - Buncombe
 - Durham
 - Forsyth
 - New Hanover
 - Pitt
 - Mecklenburg
 - Wake
- These LHDs have agreed to store vaccine and assist with transport to nearby LHDs as needed (with support from the state)
 - Vaccines arrived this week
 - Some additional doses had already been received in NC for response to initial cases

Phase 2 – PEP & PrEP

- Consider expansion to additional counties – **Pending amount of vaccine available**
 - Based on populations of persons living with HIV, other STIs, MSM population estimates
- Expect vaccination to include PrEP of certain groups – **Pending additional CDC guidance**
 - NCDHHS working with local health departments and other partners to develop allocation plans
 - Focus on equity and access, including in underserved areas
 - Clinics that receive HRSA funding will have separate federal allocation clinics



Draft and subject to change based on new information

Phase 1 Eligibility

- People who have been in close physical contact in the past 14 days with someone diagnosed with monkeypox, or
- People who know their sexual partner was diagnosed with monkeypox, or
- Men who have sex with men, or transgender individuals, who have had multiple or anonymous sex partners in the last 14 days in either a venue where monkeypox was present or in an area where the virus is spreading.^[1]
- ^[1] Currently, this includes several locations in Europe and parts of the following U.S. jurisdictions: California, District of Columbia, Florida, Illinois, Massachusetts, New York, and Texas. Updated global and U.S. case numbers are posted on the CDC site [here](#)



BACK TO SCHOOL IMMUNIZATIONS

NIAM August 2022

National Immunization Awareness Month (NIAM) is an annual observance held in August to highlight the importance of vaccination for people of all ages.

NC DHHS is supporting this initiative with key messages aimed at families, immunization providers and stakeholders.

Focus on the importance of child and adolescent immunization as students head back to school.




**National Immunization
Awareness Month**

#ivax2protect

NC BACK TO SCHOOL Immunization Requirements

Grade Level Entry Vaccine Requirements*

	DTaP	5 doses
	Polio	4 doses
	Hib (4-YEAR-OLDS ONLY)	3-4 doses
	MMR (or 2 measles, 2 mumps, 1 rubella)	2 doses
	Hepatitis B	3 doses
	Varicella	2 doses
	Pneumococcal conjugate (4-YEAR-OLDS ONLY)	4 doses

** At all ages and grades, the number of doses required may vary by a child's age and when they were vaccinated.*



NC Department of Health and Human Services • Division of Public Health •
Women's and Children's Health Section • Immunization Branch •
www.immunize.nc.gov/ • NCDHHS is an equal opportunity employer and
provider • 02/2020



NC BACK TO SCHOOL Immunization Requirements

Seventh Grade Entry Vaccine Requirements*

7th

DTaP	5 doses
Polio	4 doses
MMR (or 2 measles, 2 mumps, 1 rubella)	2 doses
Hepatitis B	3 doses
Varicella	1 dose
Tdap	1 dose
Meningococcal conjugate	1 dose

** At all ages and grades, the number of doses required may vary by a child's age and when they were vaccinated.*




NC BACK TO SCHOOL Immunization Requirements

Twelfth Grade Entry Vaccine Requirements*

12th

DTaP	5 doses
Polio	4 doses
MMR (or 2 measles, 2 mumps, 1 rubella)	2 doses
Hepatitis B	3 doses
Varicella	1 dose
Tdap	1 dose
Meningococcal conjugate (EFFECTIVE 2020-21 SCHOOL YEAR)	2 doses

** At all ages and grades, the number of doses required may vary by a child's age and when they were vaccinated.*



Questions?